Cargando…

The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs

Infection with hepatitis B virus (HBV) is a worldwide health problem. Chronic hepatitis B can lead to fibrosis, liver cirrhosis, and hepatocellular carcinoma (HCC). Management of the latter two conditions often requires liver transplantation. Treatment with conventional interferon or pegylated inter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Nidhi, Goyal, Milky, Wu, Catherine H., Wu, George Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	XIA & HE Publishing Ltd 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548360/ https://www.ncbi.nlm.nih.gov/pubmed/26357626 http://dx.doi.org/10.14218/JCTH.2014.00021

Ejemplares similares

Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas
por: Wei, Yanyan, et al.
Publicado: (2019)

The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment
por: Wu, Lina, et al.
Publicado: (2021)

Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs
por: Siakavellas, Spyros, et al.
Publicado: (2021)

Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy
por: Jiang, Bei, et al.
Publicado: (2022)

Impact of nucleos(t)ide analog treatment on the development of malignancy in patients with chronic hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2018)

Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score
por: Kaneko, Shun, et al.
Publicado: (2020)

Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients
por: Scheller, Laura, et al.
Publicado: (2021)

Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China
por: Zhao, Youyun, et al.
Publicado: (2016)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015)

Predictors of Sustained Virologic Response after Discontinuation of Nucleos(t)ide Analog Treatment for Chronic Hepatitis B
por: Peng, Jie, et al.
Publicado: (2015)

High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs
por: Lin, Ching-Chung, et al.
Publicado: (2019)

Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy
por: Liu, Li
Publicado: (2020)

Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2021)

Antiviral activities of two nucleos(t)ide analogs against vaccinia and mpox viruses in primary human fibroblasts
por: Dsouza, Lara, et al.
Publicado: (2023)

Renal Function in Nucleos(t)ide Analog-Treated Patients With Chronic Hepatitis B: A Systematic Literature Review and Network Meta-Analysis
por: Chan, Henry L. Y., et al.
Publicado: (2016)

Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection
por: Zhang, Xiaoman, et al.
Publicado: (2019)

Frequency and Mutation Patterns of Resistance in Patients with Chronic Hepatitis B Infection Treated with Nucleos(t)ide Analogs in Add-On and Switch Strategies
por: Sayan, Murat, et al.
Publicado: (2011)

Serum HBV RNA Dynamic and Drug Withdrawal Predictor Value in Patients With Chronic HBV Infection on Long-term Nucleos(t)ide Analogue (NA) Therapy
por: Liu, Yayun, et al.
Publicado: (2020)

Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population
por: López-Cortés, Luis F., et al.
Publicado: (2014)

Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy
por: Osiowy, Carla, et al.
Publicado: (2016)

Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs
por: Li, Tao, et al.
Publicado: (2018)

Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss
por: Xue, Yan, et al.
Publicado: (2021)

The 96-week clinical outcomes after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients
por: Xu, Wen-Xiong, et al.
Publicado: (2021)

Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog
por: Hui, Vicki Wing-Ki, et al.
Publicado: (2021)

Corrigendum: Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2022)

Antiviral activities of two nucleos(t)ide analogs against vaccinia, mpox, and cowpox viruses in primary human fibroblasts
por: Dsouza, Lara, et al.
Publicado: (2023)

HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining
por: Xu, Xizhan, et al.
Publicado: (2017)

Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues
por: Wang, Yang, et al.
Publicado: (2022)

Circulating miR-122 Is a Predictor for Virological Response in CHB Patients With High Viral Load Treated With Nucleos(t)ide Analogs
por: Wu, Yin, et al.
Publicado: (2019)

Dynamics of Serum Pregenome RNA in Chronic Hepatitis B Patients Receiving 96-Month Nucleos(t)ide Analog Therapy
por: Tao, Yachao, et al.
Publicado: (2022)

Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2011)

The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis
por: Cholongitas, Evangelos, et al.
Publicado: (2015)

Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor–Sparing Antiretroviral Therapy in a High–HBV Endemicity Setting
por: Abdullahi, Adam, et al.
Publicado: (2018)

Editorial: serum HBV RNA biphasic decline in patients with HBeAg‐positive chronic hepatitis B treated with nucleos(t)ide analogues
por: Ding, Yang, et al.
Publicado: (2020)

The efficiency of low-dose hepatitis B immunoglobulin plus nucleos(t)ide analogs in preventing posttransplant hepatitis B virus recurrence
por: VATANSEVER, Sezgin, et al.
Publicado: (2019)

The Impact of Nucleos(t)ide Analogs Off-Therapy Among Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis
por: Wang, Mian, et al.
Publicado: (2021)

The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis
por: Wen, Xiaotong, et al.
Publicado: (2021)

Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog
por: Uchida, Yoshihito, et al.
Publicado: (2022)

Corrigendum: Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor–Sparing Antiretroviral Therapy in a High–HBV Endemicity Setting
por: Abdullahi, Adam, et al.
Publicado: (2019)

Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2tctnqaqhuaqikkt8a68e4vbp6